INV103 / Invion - LARVOL DELTA

Invion three phase (Investing.com) - Anticipated P2 trial completion for lupus in July 2014.

Anticipated trial completion date • Lupus

Invion announces commencement of phase II clinical trial in lupus (Invion Press Release) - "Invion...announce the initiation and commencement of patient enrolment in the company’s phase II clinical trial of INV103 (ala-Cpn10) in patients with mild systemic lupus erythematosus...the drug market for which is expected to reach sales of over $4 billion in the US and five major EU markets by 2020...Commencement follows acceptance by the FDA of Invion’s IND...safety and efficacy data from the first two cohorts available in approximately six months."

Anticipated P2 data • Anticipated sales • Enrollment open • FDA event • Lupus

Efficacy and safety of subcutaneous chaperonin 10 in patients with active RA despite methotrexate treatment (CBio) - P2, N=155; Primary endpoint of ACR20 at week 12 was not achieved; Significant & dose related changes were evident between placebo & 75mg Cpn10 in the following: ACR-N response (p<0.05), time to ACR50 response, tender and swollen joint counts, SF-36 general health, social functioning and role emotional domains, mental component score, and SF-6D health utility index

P2 data • Rheumatoid Arthritis

Effect of Tim23 Knockdown in vivo on Mitochondrial Protein Import and Retrograde Signaling to the UPRmt in Muscle. (PubMed, Am J Physiol Cell Physiol) - "...This import defect activated the C/EBP homologous protein (CHOP) branch of the UPR, as evident from increases in caseinolytic mitochondrial matrix peptidase proteolytic subunit (ClpP) and chaperonin 10 (cpn10) but not the activating transcription factor 5 (ATF5) arm...Our data suggest that mitochondrial proteolytic byproducts exert an inhibitory effect on protein import, possibly to reduce excessive protein import as a potential negative feedback mechanism. The inhibition of import into the organelle also serves a retrograde function, possibly via ROS emission, to modify nuclear gene expression and ultimately improve folding capacity."

Journal • Preclinical